Drug regulator in India orders clinical trials of generics

01/21/2013 | BioSpectrum Asia

The Drug Controller General of India, which regulates the country's pharmaceuticals, has asked drugmakers to conduct clinical trials of all generic drugs and seek approval within 18 months. The move is in response to abuse of legal loopholes that enabled some companies to bypass DGCI and sell drugs with dangerous side effects, many of which are banned abroad.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Director of Operations - GBS
Mayo Clinic
MN